600479.SHG ZhuZhou QianJin Pharmaceutical Co Ltd
- Market cap
- CNY 5.36B
- P/E
- 14.7x
- P/B
- 1.71x
- ROE
- 11.1%
- Dividend yield
- 2.85%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600479.SHG undervalued?
Graham number600479.SHG trades 5.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ZhuZhou QianJin Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for ZhuZhou QianJin Pharmaceutical Co Ltd yet.
ZhuZhou QianJin Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ZhuZhou QianJin Pharmaceutical Co Ltd
ZhuZhou QianJin Pharmaceutical Co.,Ltd engages in the production and sales of Chinese and Western medicines in China. The company offers traditional chinese medicine that cover areas, such as pelvic inflammatory disease, menstrual disorders, cervicitis, dysfunctional uterine bleeding, breast hyperplasia, postpartum blood and qi deficiency, and menopausal syndrome; chemical products that covers areas, including gynecology, cardiovascular system, endocrine system, liver and ki…
Full company profileZhuZhou QianJin Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ZhuZhou QianJin Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.86B | 3.18B | 3.33B | 3.53B | 3.63B | 3.66B | 4.03B | 3.80B | 3.63B | 3.63B | 3.79B |
| Gross Profit | 1.29B | 1.43B | 1.55B | 1.60B | 1.59B | 1.63B | 1.73B | 1.75B | 1.68B | 3.63B | 1.86B |
| Operating Income | 194M | 296M | 337M | 431M | 424M | 436M | 444M | 462M | 332M | 441M | 417M |
| EBITDA | 261M | 352M | 415M | 491M | 488M | 503M | 521M | 547M | 420M | 515M | 417M |
| Net Income | 149M | 208M | 255M | 294M | 297M | 302M | 303M | 320M | 231M | 288M | 344M |
| EPS | 0.36 | 0.50 | 0.61 | 0.70 | 0.71 | 0.72 | 0.71 | 0.76 | 0.56 | 0.64 | 0.70 |
| Balance Sheet | |||||||||||
| Total Assets | 3.03B | 3.29B | 3.47B | 3.81B | 4.23B | 4.06B | 4.62B | 4.68B | 4.56B | 4.96B | 5.17B |
| Total Liabilities | 948M | 1.05B | 1.04B | 1.18B | 1.47B | 1.36B | 1.82B | 1.65B | 1.42B | 1.61B | 1.74B |
| Shareholders' Equity | 1.75B | 1.88B | 2.03B | 2.18B | 2.27B | 2.15B | 2.22B | 2.39B | 2.46B | 3.03B | 3.10B |
| Cash & Short-term Investments | 736M | 690M | 1.10B | 1.38B | 1.41B | 1.42B | 1.91B | 2.00B | 1.35B | 780M | 706M |
| Total Debt | 47.8M | 38.3M | 27.7M | 22.4M | 197M | 149M | 124M | 117M | 433M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 141M | 283M | 383M | 155M | 542M | 486M | 733M | 443M | 399M | 480M | - |
| Capital Expenditure | 81.5M | 57.3M | 46.4M | 40.6M | 97.2M | 71.9M | 34.4M | 44.0M | 47.3M | 124M | 103M |
| Free Cash Flow | 59.4M | 226M | 337M | 115M | 445M | 414M | 699M | 399M | 351M | 356M | 243M |
| Ratios | |||||||||||
| ROE | 8.6% | 11.1% | 12.6% | 13.5% | 13.1% | 14.0% | 13.6% | 13.4% | 9.4% | 9.5% | 11.1% |
| ROA | 4.9% | 6.3% | 7.4% | 7.7% | 7.0% | 7.4% | 6.5% | 6.9% | 5.1% | 5.8% | 6.6% |
| Net Profit Margin | 5.2% | 6.5% | 7.7% | 8.3% | 8.2% | 8.2% | 7.5% | 8.4% | 6.4% | 7.9% | 9.1% |
| Debt to Equity | 0.03x | 0.02x | 0.01x | 0.01x | 0.09x | 0.07x | 0.06x | 0.05x | 0.18x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ZhuZhou QianJin Pharmaceutical Co Ltd dividends
- Dividend yield
- 2.85%
- Forward dividend
- 0.56 CNY
- Payout ratio
- 53.0%
- Ex-dividend date
- Oct 27, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 153M | 0.34 | 53.0% |
| 2024 | CNY 153M | 0.37 | 66.2% |
| 2023 | CNY 150M | 0.35 | 46.7% |
| 2022 | CNY 249M | 0.58 | 82.2% |
| 2021 | CNY 430M | 1.03 | 142.2% |
| 2020 | CNY 209M | 0.50 | 70.4% |
| 2019 | CNY 167M | 0.40 | 56.9% |
| 2018 | CNY 105M | 0.25 | 41.1% |
| 2017 | CNY 71.4M | 0.17 | 34.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.2:1 on Jun 15, 2018.
Who owns ZhuZhou QianJin Pharmaceutical Co Ltd
- Insiders 40.87%
- Institutions 5.37%
- Public & others 53.76%
- Shares outstanding 492M
- Free float 314M
ZhuZhou QianJin Pharmaceutical Co Ltd company profile
- Company name
- ZhuZhou QianJin Pharmaceutical Co Ltd
- Ticker
- 600479.SHG
- ISIN
- CNE000001GX3
- Exchange
- Shanghai Stock Exchange
- Listed since
- Feb 26, 2004
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 5,041
- Fiscal year end
- December
- Address
- No. 801 Zhuzhou Avenue, Zhuzhou, China, 412007
- Phone
- 86 18 774834452
- Website
- qjyy.com
About ZhuZhou QianJin Pharmaceutical Co Ltd
ZhuZhou QianJin Pharmaceutical Co.,Ltd engages in the production and sales of Chinese and Western medicines in China. The company offers traditional chinese medicine that cover areas, such as pelvic inflammatory disease, menstrual disorders, cervicitis, dysfunctional uterine bleeding, breast hyperplasia, postpartum blood and qi deficiency, and menopausal syndrome; chemical products that covers areas, including gynecology, cardiovascular system, endocrine system, liver and kidney diseases, oncology and immune system, antiviral, psychotropic, and tonic products; API; TCM derivatives; and hygienic products, such as gynaecological and baby nursing, and maternity pad/ maternity package. It is also involved in the provision of prepared slices of Chinese medicinal herbs; planting and sales of Chinese medicinal materials; sales of Class I and Class II medical devices, as well as food, wine, beverages, tea, bulk food, hygiene and disinfection products, cosmetics and hygiene products, disinfectants, health care products, agricultural products, daily necessities, and bee products; wholesale and retail of pharmaceuticals, movies, video screenings, video games, cold drinks, tobacco, alcohol, and non-staple foods; equity investment and investment consulting activities. ZhuZhou QianJin Pharmaceutical Co.,Ltd was founded in 1966 and is headquartered in Zhuzhou, China.
ZhuZhou QianJin Pharmaceutical Co Ltd management
7- Mr. Zhiyong ChenGeneral Manager · born 1977
- Ms. Yunjiao OuyangDeputy General Manager · born 1972
- Ms. Li ZhuBoard secretary · born 1977
- Mr. Aiwei XieDeputy General Manager · born 1968
- Mr. Yun GongDeputy General Manager · born 1969
- Ms. Yihua PengDeputy General Manager · born 1973
- Zhouyang WangAccounting Supervisor